Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Income from Continuing Operations (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Income from Continuing Operations for 6 consecutive years, with 54920000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 27.74% to 54920000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 275702000.0 through Dec 2025, up 18.36% year-over-year, with the annual reading at 275703000.0 for FY2025, 18.36% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 54920000.0 at Relay Therapeutics, up from 73984000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 42184000.0 in Q1 2021, with the low at 193400000.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 80488250.0, with a median of 76405500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations plummeted 623.69% in 2021, then soared 60.29% in 2022.
  • Over 5 years, Income from Continuing Operations stood at 67456000.0 in 2021, then dropped by 0.03% to 67479000.0 in 2022, then decreased by 23.74% to 83496000.0 in 2023, then increased by 8.97% to 76005000.0 in 2024, then grew by 27.74% to 54920000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 54920000.0, 73984000.0, and 69742000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.